Loading
A Chinese trial showing that a PD-1 antibody plus a bevacizumab copy extends life in liver cancer, mirroring the global IMbrave150 result in a hepatitis B population.
571 patients randomised 2:1. Overall survival hazard ratio 0.57 (median not reached versus 10.4 months) and progression-free survival hazard ratio 0.56 at the first interim analysis; about 94% of patients had hepatitis B, the cause of most Chinese liver cancer. NMPA approval June 2021. With IMbrave150 it established anti-PD-(L)1 plus anti-VEGF as the first-line standard and gave China a reimbursed domestic option.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Innovent Biologics, Sintilimab, Immune checkpoint inhibitors and the tag china.
Shares Innovent Biologics, Sintilimab and the tag china.
Shares Innovent Biologics, Sintilimab, Immune checkpoint inhibitors and the tag china.
Shares Sorafenib, Hepatocellular carcinoma and the tag china.
Shares Innovent Biologics and the tag china.
Shares Sintilimab and the tag china.
Shares Anti-angiogenic therapy, Hepatocellular carcinoma and the tag china.
Shares Innovent Biologics and the tag china.